ArticleAmerican journal of translational research2013
Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer.
Article in American journal of translational research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Circulating microRNA profiles and the identification of miR-593 and miR-511 which directly target the PROP1 gene in children with combined pituitary hormone deficiency.International journal of molecular medicine · 2015Trial
- Emerging Molecular Technology in Cancer Testing.EJIFCC · 2024Review
- Review
- A Study to Investigate the Role of Noncoding RNA miR146 Alpha as a Potential Biomarker in Prostate Cancer.Journal of analytical oncology · 2022Article
- Long Non-coding RNA FEZF1-AS1 Promotes Growth and Reduces Apoptosis Through Regulation of miR-363-3p/PAX6 Axis in Retinoblastoma.Biochemical genetics · 2021Article
- A health disparities study of MicroRNA-146a expression in prostate cancer samples derived from African American and European American patients.Journal of solid tumors · 2020Article
- A novel tumor suppressing gene,Oncology letters · 2020Article
- The State of the Art on Blood MicroRNAs in Pancreatic Ductal Adenocarcinoma.Analytical cellular pathology (Amsterdam) · 2019Review
- Epigenetic silencing of miR-137 induces resistance to bicalutamide by targeting TRIM24 in prostate cancer cells.American journal of translational research · 2019Article
- Long intergenic noncoding RNA-p21 inhibits apoptosis by decreasing PUMA expression in non-small cell lung cancer.The Journal of international medical research · 2019Article
- New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.Frontiers in oncology · 2018Review
- Expression level of microRNA-200c is associated with cell morphology in vitro and histological differentiation through regulation of ZEB1/2 and E-cadherin in gastric carcinoma.Oncology reports · 2018Article
- miR-145 regulates the proliferation and apoptosis of Y79 human retinoblastoma cells by targeting IGF-1R.International journal of clinical and experimental pathology · 2018Article
- Article
- Insights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic intervention.World journal of hepatology · 2016Review
- Genome-wide association studies and epigenome-wide association studies go together in cancer control.Future oncology (London, England) · 2016Article
- MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions.World journal of gastrointestinal oncology · 2016Review
- Sestrin2 expression is a favorable prognostic factor in patients with non-small cell lung cancer.American journal of translational research · 2016Article
- Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?Korean journal of urology · 2015Review
- Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
This study was focused on molecular profiling of prostate cancer (PCa) using scant amounts of both frozen and formalin-fixed paraffin-embedded (FFPE) PCa tissue specimens. DNA and RNA were extracted and interrogated for: (1) whole-genome gene expression profiling, (2) miRNA expression analysis, (3) SNP analysis, and (4) mutation analysis. Data was statistically analyzed and correlated with clinical and pathologic variables. Expression profiling of 47,224 genes revealed 74 genes that were significant in predicting high tumor grade in PCa (p<0.0001). These were involved in many cellular processes as analyzed by Ingenuity Pathway Analysis (IPA). Using novel high throughput technologies, we identified a specific oncogenomic and miRNA signatures showing loss of miR-34 expression. Interestingly, p53 was at the center hub of the signaling pathways, and the loss of miR-34a expression was consistent with the central role of p53 in PCa. Analysis of 731,442 SNP's, revealed 638 SNP's that were significant in predicting high tumor grade (p<0.0001; logistic regression analysis). We also found, for the first time, a novel hot spot mutation in MET oncogene, variant T992I, suggesting that our findings would be useful in further defining the role of specific regulatory genes and miRNAs in the pathological evolution of PCa, and could also have potential clinical utility in improving diagnostic accuracy, refining prognostic and predictive capabilities and may serve as therapeutic targets.
Indexed as
Identifiers
23573364PMC3612515W174753961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.